Comparative Prospective Study of the Effectiveness and Safety of Russian of the Russian Botulinum Toxin-a Relatox ® in Order to Correct the of Masticatory Muscles Hypertone Patients With Myofascial Pain Syndrome

Abstract

Treatment of diseases of the temporomandibular joint (TMJ), complicated by hypertension of the masticatory muscles, remains one of the unsolved problems of dentistry. The purpose of this clinical study is to assess the safety and efficacy of the first Russian botulinum toxin a (BTA) Relatox® for the correction of masticatory muscle hypertension in patients with myofascial pain syndrome, as well as its comparison with the Lantox® by these parameters. Injections of botulinum toxin type A are a method of treatment in patients with myofascial facial pain syndrome with high therapeutic potential. The analysis of clinical results of using the Russian botulinum toxin type A of Relatox® shows high clinical efficacy. Comparative analysis of Lantox® and Relatox® showed no differences in safety and efficacy.

Clinical and Anatomical Requirements and Indications for Using a Novel Multifunctional Gnatic Device

“…local and general factors [1]. The consequence of muscle hypertonia is the activation of anaerobic glycolysis, accompanied by the accumulation of lactic acid, which in turn irritates pain receptors, causing aggravation of pain symptoms [2,11]. The emergence of a painful effect is a stressor agent, which leads to a more forced muscle spasm [10], against the background of the production of adrenaline.…”